Abstract:Disruption of epigenetic processes to eradicate tumor cells is among the most promising interventions for cancer control. EZH2 (Enhancer of zeste homolog 2), a catalytic component of polycomb repressive complex 2 (PRC2), methylates lysine 27 of histone H3 to promote transcriptional silencing and is an important drug target for controlling cancer via epigenetic processes. In the present study, we have developed various predictive models for modeling the inhibitory activity of EZH2. Binary and multiclass models were built using SVM, random forest and XGBoost methods. Rigorous validation approaches including predictiveness curve, Y-randomization and applicability domain (AD) were employed for evaluation of the developed models. Eighteen descriptors selected from Boruta methods have been used for modeling. For binary classification, random forest and XGBoost achieved an accuracy of 0.80 and 0.82, respectively, on external test set. Contrastingly, for multiclass models, random forest and XGBoost achieved an accuracy of 0.73 and 0.75, respectively. 500 Y-randomization runs demonstrate that the models were robust and the correlations were not by chance. Evaluation metrics from predictiveness curve show that the selected eighteen descriptors predict active compounds with total gain (TG) of 0.79 and 0.59 for XGBoost and random forest, respectively. Validated models were further used for virtual screening and molecular docking in search of potential hits. A total of 221 compounds were commonly predicted as active with above the set probability threshold and also under the AD of training set. Molecular docking revealed that three compounds have reasonable binding energy and favorable interactions with critical residues in the active site of EZH2. In conclusion, we highlighted the potential of rigorously validated models for accurately predicting and ranking the activities of lead molecules against cancer epigenetic targets. The models presented in this study represent the platform for development of EZH2 inhibitors.

Conformation-dependent QSAR approach for the prediction of inhibitory activity of bromodomain modulators

BET bromodomain inhibitors: fragment-based in silico design using multi-target QSAR models

3D‐QSAR, Molecular Docking and Molecular Dynamics Analysis of 1,2,3,4‐tetrahydroquinoxalines As BRD4/BD2 Inhibitors

Identification of Novel Bromodomain-Containing Protein 4 (BRD4) Binders through 3D Pharmacophore-Based Repositioning Screening Campaign

Large scale comparison of QSAR and conformal prediction methods and their applications in drug discovery

Combined Pharmacophore Models As Virtual Screening Protocol Against BRD4(1) Inhibitor

Insight into the key interactions of bromodomain inhibitors based on molecular docking, interaction fingerprinting, molecular dynamics and binding free energy calculation.

A Theoretical Insight into Selectivity of Inhibitors Toward Two Domains of Bromodomain-Containing Protein 4 Using Molecular Dynamics Simulations

Machine-Learning-Assisted Approach for Discovering Novel Inhibitors Targeting Bromodomain-Containing Protein 4.

Binding Kinetics Versus Affinities in BRD4 Inhibition

Theoretical Research in Structure Characteristics of Different Inhibitors and Differences of Binding Modes with CBP Bromodomain

Theoretical Exploration of the Binding Selectivity of Inhibitors to BRD7 and BRD9 with Multiple Short Molecular Dynamics Simulations

Initial Development of Automated Machine Learning-Assisted Prediction Tools for Aryl Hydrocarbon Receptor Activators

Identification of novel natural product inhibitors of BRD4 using high throughput virtual screening and MD simulation

QSAR study of cinnamylphenol derivatives as EBV-EA inhibitors

Prediction of Inhibitory Activity of Epidermal Growth Factor Receptor Inhibitors Using Grid Search-Projection Pursuit Regression Method

QSAR Regression Models for Predicting HMG-CoA Reductase Inhibition

Molecular mechanism study of several inhibitors binding to BRD9 bromodomain based on molecular simulations

Molecular mechanism of inhibitor bindings to bromodomain-containing protein 9 explored based on molecular dynamics simulations and calculations of binding free energies

Development of Machine Learning Models for Accurately Predicting and Ranking the Activity of Lead Molecules to Inhibit PRC2 Dependent Cancer

Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery